DPP-4 Therapy Center - Diabetes In Control

Dipeptidyl Peptidase-4 Role in Patients with Renal Transplant

2 weeks ago Articles, DPP-4 Therapy Center, Nephrology, Type 2 Diabetes

Diabetes management can be a major factor in renal transplant aftercare; can DPP-4 therapy help improve outcomes?

Sitagliptin Associated With Reduced Mortality In Diabetes Patients With COVID-19

Nov 10, 2020 DPP-4 Therapy Center

Patients taking the DPP-4 inhibitor sitagliptin had lower risk of needing intensive care or needing mechanical ventilation.

Another Oral Combination Antidiabetic Agent

Oct 24, 2020 Articles, DPP-4 Therapy Center, SGLT-2 Therapy Center

Dual and triple therapy just got a little easier.

Do DPP-4 Inhibitors Increase Risk of Pneumonia in Patients with T2D?

Oct 17, 2020 DPP-4 Therapy Center, Type 2 Diabetes

Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.

Examining the Risks of Antihyperglycemic Dual and Triple Therapies for T2D

Aug 29, 2020 DPP-4 Therapy Center, GLP-1 Agonist Therapy Center, Metformin Therapy Center, SGLT-2 Therapy Center, Sulfonylurea, Type 2 Diabetes

A closer look at the risk of major adverse events, severe hypoglycemia, and all-cause mortality for commonly used therapies in treating type 2 diabetes.

Could a Diabetes Medication Affect COVID-19 Outcomes?

Jun 13, 2020 DPP-4 Therapy Center

Research into the interaction of DPP4 and coronavirus may be a step toward a cure.

New CV Outcomes Trials Examine Linagliptin and Glimepiride Among Patients With High CVD Risk

Mar 3, 2020 Cardiology, DPP-4 Therapy Center, Paid, Sulfonylurea

The CAROLINA and CARMELINA Trials offer further information regarding the CV safety of linagliptin and glimepiride among patients with T2DM, high CVD risk, and decreased renal function.